New Delhi Metallo-beta-lactamase-1 (NDM-1) is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infection, among those Acinetobacter and more specifically Acinetobacter baumannii. Here are some links to studies that include a look at the relationship of NDM-1 and A. baumannii.
Co-occurrence of blaNDM-1 with blaOXA-23 or blaOXA-58 in clinical multidrug-resistant Acinetobacter baumannii isolates in Algeria aimed to study aim of this study was to characterize the mechanisms of carbapenem resistance in Acinetobacter baumannii strains isolated in an Algerian hospital. It reports “or the first time the co-occurrence of blaNDM-1 along with blaOXA-23 or blaOXA-58 in recent clinical isolates of A. baumannii from Northeast Algeria. These findings re-emphasize the dissemination and rapid spread of blaNDM-1 carbapenemase genes in multidrug-resistant clinical A. baumannii isolates in Algeria.”
Draft genome sequence of a multidrug-resistant New Delhi metallo-β-lactamase NDM-1-producing Acinetobacter pittii sequence type 207 isolate from China notes that the increasing emergence of carbapenem-resistant Acinetobacter spp. worldwide has resulted in the limited availability of effective antimicrobial agents and has become a major public health concern.
Multidrug Resistant Acinetobacter reports that “there is an urgent need to enforce infection control measures and antimicrobial stewardship programs to prevent the further spread of these resistant Acinetobacter species and to delay the emergence of increased resistance in the bacteria.”
Previously, at our blog: